|This article needs additional citations for verification. (March 2013)|
Cangene Corporation was a pharmaceutical/biopharmaceutical company based in Winnipeg. Manitoba, Canada. It was founded in 1984 and specialized in hyperimmunes, contract manufacturing, biopharmaceuticals and biodefense. The company operates eight locations across North America and employs over 600 mostly in Winnipeg or in Baltimore at Cangene bioPharma (which is responsible for contract manufacturing).
In 2013, the company purchased rights to development and commercialization of three drug candidates, recombinant blood clotting factors VIIa, VIII and IX, the latter of which is in clinical trials.
- "." Cangene. Retrieved on 5 Aug 2013.
- "Cangene inks $300+M deal for bankrupt Inspiration's IB1001", Genetic Engineering & Biotechnology News (paper ed.) 33 (6), March 15, 2013: 8
- Press Release (21 February 2014). "Emergent BioSolutiions Completes Acquisition of Cangene Corporation". Emgergent Biosolutions. Retrieved 17 June 2014.